57 related articles for article (PubMed ID: 9002758)
1. Description of a multicompartmental model of the biodistribution of 111In-DTPA-D-Phe-1-octreotide in human.
D'addabbo A; Simeone G; Rubini G; Nitti L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):86-9. PubMed ID: 9002758
[TBL] [Abstract][Full Text] [Related]
2. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo.
Akizawa H; Arano Y; Uezono T; Ono M; Fujioka Y; Uehara T; Yokoyama A; Akaji K; Kiso Y; Koizumi M; Saji H
Bioconjug Chem; 1998; 9(6):662-70. PubMed ID: 9815158
[TBL] [Abstract][Full Text] [Related]
3. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
4. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
5. Radiation dosimetry for indium-111-pentetreotide.
Stabin MG; Kooij PP; Bakker WH; Inoue T; Endo K; Coveney J; de Jong R; Minegishi A
J Nucl Med; 1997 Dec; 38(12):1919-22. PubMed ID: 9430470
[TBL] [Abstract][Full Text] [Related]
6. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
7. 111In-DTPA-D-Phe-1-octreotide scintigraphy of small cell lung cancer.
Bombardieri E; Chiti A; Crippa F; Seregni E; Cataldo I; Maffioli L; Soresi E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):104-7. PubMed ID: 9002763
[TBL] [Abstract][Full Text] [Related]
8. A comparison of biodistribution between 111In-DTPA octreotide and 111In-DOTATOC in rats bearing pancreatic tumors.
Lin YC; Hung GU; Luo TY; Chen CH; Hsia CC; Hen SL; Ho YJ; Lin WY
J Vet Med Sci; 2006 Apr; 68(4):367-71. PubMed ID: 16679728
[TBL] [Abstract][Full Text] [Related]
9. Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.
Laznickova A; Laznicek M; Trejtnar F; Melicharova L; Suzuki KH; Akizawa H; Arano Y; Yokoyama A
Eur J Drug Metab Pharmacokinet; 2002; 27(1):37-43. PubMed ID: 11996325
[TBL] [Abstract][Full Text] [Related]
10. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of (111)In labeled somatostatin analogs for targeted therapy of somatostatin receptor positive tumors.
Bernhardt P; Ahlman H; Nilsson O; Benjegård SA; Forssell-Aronsson E
Cancer Biother Radiopharm; 2003 Apr; 18(2):249-52. PubMed ID: 12804051
[No Abstract] [Full Text] [Related]
12. Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide.
Forssell-Aronsson E; Bernhardt P; Nilsson O; Tisell LE; Wängberg B; Ahlman H
Acta Oncol; 2004; 43(5):436-42. PubMed ID: 15360047
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evaluation of safety, pharmacokinetics and dosimetry of the somatostatin analog 111In-DTPA-D-Phe-octreotide--report of the phase 1 study].
Inoue T; Ootake H; Hirano T; Tomiyoshi K; Endo K; Tanaka K; Shimizu N; Saito T
Kaku Igaku; 1995 May; 32(5):511-21. PubMed ID: 7596072
[TBL] [Abstract][Full Text] [Related]
14. Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-D-Phe1-octreotide.
Bass LA; Lanahan MV; Duncan JR; Erion JL; Srinivasan A; Schmidt MA; Anderson CJ
Bioconjug Chem; 1998; 9(2):192-200. PubMed ID: 9548534
[TBL] [Abstract][Full Text] [Related]
15. Effect of stereochemistry on the clearance mechanism of 111In(III)-labeled D- or L-benzyldiethylenetriaminepentaacetic acid.
Deal KA; Welch MJ
J Med Chem; 1997 Nov; 40(24):3986-9. PubMed ID: 9397181
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW
Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971
[TBL] [Abstract][Full Text] [Related]
17. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes.
Duncan JR; Stephenson MT; Wu HP; Anderson CJ
Cancer Res; 1997 Feb; 57(4):659-71. PubMed ID: 9044843
[TBL] [Abstract][Full Text] [Related]
18. Radiation doses deriving from patients undergoing 111In-DTPA-D-Phe-1-octreotide scintigraphy.
Cormack J
Eur J Nucl Med; 1998 Apr; 25(4):442-4. PubMed ID: 9643971
[No Abstract] [Full Text] [Related]
19. In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas.
Robben JH; Visser-Wisselaar HA; Rutteman GR; van Rijk PP; van Dongen AJ; Voorhout G; van den Ingh TS; Hofland LJ; Lamberts SW
J Nucl Med; 1997 Jul; 38(7):1036-42. PubMed ID: 9225787
[TBL] [Abstract][Full Text] [Related]
20. Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose.
Rolleman EJ; Krenning EP; Van Gameren A; Bernard BF; De Jong M
J Nucl Med; 2004 Apr; 45(4):709-13. PubMed ID: 15073269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]